Highlights

  • Fiscal 2026 revenue rose 14% to $254.2 billion, with GAAP diluted EPS of $7.23 and non-GAAP diluted EPS of $11.26.
  • Cardinal Health completed the roughly $1.9 billion Solaris Health acquisition on November 3, 2025, adding more than 750 providers.
  • Cardinal Health's board approved a $5.0 billion repurchase program on August 4, and a $4.0 billion credit facility followed.
  • Management guided fiscal 2027 non-GAAP EPS to $12.40 to $12.60, or 13% to 15% growth over an adjusted baseline.

Cardinal Health (NYSE:CAH) shares were trading near their 52-week high at USD 257.33 on October 21, 2026, down 0.09%. The healthcare services and products group closed its $1.9 billion Solaris Health acquisition in November 2025, approved a $5.0 billion buyback and signed a $4.0 billion credit facility in early August, and reported fiscal 2026 results on August 11 with guidance for fiscal 2027.

Based in Dublin, Ohio, Cardinal Health is an Ohio corporation formed in 1979 that supplies pharmaceuticals, medical products and services to hospitals, pharmacies, laboratories, physician offices and patients at home. It reports two segments: Pharmaceutical and Specialty Solutions, which distributes branded, generic and specialty drugs and includes physician-office management platforms, and Global Medical Products and Distribution, which makes, sources and distributes medical, surgical and laboratory products. Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight Logistics sit in Other. Its fiscal year ends June 30, and it had about 63,900 employees.

Revenue Up 14% on Branded and Specialty Pharmaceutical Sales

Revenue for the fiscal year ended June 30, 2026 was $254.2 billion, up 14%. GAAP operating earnings rose 15% to $2.6 billion, and GAAP diluted EPS climbed 12% to $7.23 from $6.45. Non-GAAP operating earnings grew 30% to $3.6 billion and non-GAAP diluted EPS rose 37% to $11.26.

Pharmaceutical and Specialty Solutions revenue grew 15% to $234.8 billion, with segment profit up 23% to $2.8 billion. Global Medical Products and Distribution revenue was roughly flat at $12.7 billion, while segment profit rose 91% to $258 million. Other revenue increased 26% to $6.8 billion.

Results also carried charges. The company booked a $184 million pre-tax goodwill impairment for its Navista and Integrated Oncology Network reporting unit, which lowered GAAP diluted EPS by $0.58, and a $122 million impairment of its 16% equity interest in Outcomes. It also recorded a receivable of about $200 million for expected refunds of tariffs it paid.

Solaris, Cash Deployment and the Opioid Settlement

Through The Specialty Alliance, of which it owns about 76%, Cardinal Health bought Solaris Health, a urology management services organization with over 250 locations in 14 states, for about $1.9 billion in cash.

Operating cash flow was $5.2 billion, after $417 million of opioid litigation payments. Cash and equivalents ended the year at $4.9 billion versus $3.9 billion. The company spent $1.4 billion on accelerated share repurchases, $649 million on capital expenditures and $491 million on dividends, or $2.04 per share, and repaid $600 million of debt after issuing $1.0 billion of notes. Long-term obligations were $8.9 billion, with nothing drawn on its credit facilities.

The company has accrued $4.3 billion for national opioid litigation settlements, with most remaining payments expected through 2038. On August 7, it replaced three facilities with a consolidated $4.0 billion five-year revolver expiring in August 2031. On August 4, the board approved a new $5.0 billion repurchase program, on top of $1.4 billion remaining under the prior authorization, and declared a $0.5158 quarterly dividend.

Fiscal 2027 Guidance and Capital Plans

On the August 11 call, management guided fiscal 2027 non-GAAP EPS to $12.40 to $12.60, which is 13% to 15% growth over a fiscal 2026 baseline of $10.95 that excludes a one-time $0.31 benefit from the tariff refund.

By segment, Pharmaceutical and Specialty Solutions revenue is expected to grow 3% to 5% and profit 8% to 11%. Global Medical Products and Distribution revenue is expected to grow 2% to 4%, with profit of $200 million to $220 million.

Management also expects an effective tax rate of 19% to 20%, adjusted free cash flow of $3.5 billion to $4.0 billion, capital expenditures near $700 million and at least $1 billion of share repurchases. It said rising fuel and commodity costs bear watching and could push medical products profit toward the low end of its range. These are company estimates.